Clinical psychopharmacology of eating disorders: A research update

International Journal of Neuropsychopharmacology

Volumn 15, Issue 2, 2012, Pages 209-222

  Hay, Phillipa J ^a,b   Claudino, Angélica M ^c  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anorexia nervosa; binge eating; bulimia nervosa; treatments

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROFAROMINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MOOD STABILIZER; NALTREXONE; OLANZAPINE; PIMOZIDE; QUETIAPINE; SERTRALINE; SULPIRIDE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; ZONISAMIDE;

ADD ON THERAPY; ANOREXIA; ANOREXIA NERVOSA; ANXIETY; BINGE EATING DISORDER; BULIMIA; CEREBROSPINAL FLUID; COGNITIVE THERAPY; CONVULSION; DRUG DOSE INCREASE; DRUG EFFECT; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; EATING DISORDERS; HUMANS; PSYCHOPHARMACOLOGY;

EID: 84857358985     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000460     Document Type: Review

References (130)

1. Agras SW, Telch CF, Arnow B, Eldregde K, et al. (1994). Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder-an addictive design. Behavioural Therapy 25, 225-238. (Pubitemid 24187562)
2. Agras WS, Rossiter EM, Arnow B, Schneider JA, et al. (1992). Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. American Journal of Psychiatry 149, 82-87.
3. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Arlington, VA: American Psychiatric Publishing Inc.
4. APA (2006). Practice guidelines for the treatment of patients with eating disorders. In Practice Guidelines for the Treatment of Psychiatric Disorders, 3rd edn (pp. 1097-1222). Arlington, VA: American Psychiatric Association.
5. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, et al. (2003). A randomized, double-blind, placebocontrolled study of sibutramine in the treatment of binge eating disorder. Archives of General Psychiatry 60, 1109-1116. (Pubitemid 37429650)
6. Appolinario JC, McElroy SL (2004). Pharmacological approaches in the treatment of binge eating disorder. Current Drug Targets 5, 301-307. (Pubitemid 38372314)
7. Arnold LM, McElroy SL, Hudson JI, Welge JA, et al. (2002). A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Journal of Clinical Psychiatry 63, 1028-1033. (Pubitemid 35388063)
8. Arnone D (2005). Review of the use of topiramate for treatment of psychiatric disorders. Annals of General Psychiatry 4, 5.
9. Attia E, Haiman C, Walsh BT, Flater SR (1998). Does fluoxetine augment the inpatient treatment of anorexia nervosa? American Journal of Psychiatry, 155, 548-551. (Pubitemid 28207453)
10. Bacaltchuk J, Hay P (2003). Antidepressants vs. placebo for people with bulimia nervosa. Cochrane Database of Systematic Reviews. Issue 1, Art. No. CD003391.
11. Bacaltchuk J, Hay P, Trefiglio R (2001). Antidepressants vs. psychological treatments and their combination for bulimia nervosa. Cochrane Database of Systematic Reviews. Issue 1, Art. No. CD003385.
12. Bailer U, Frank G, Henry S, Price J, et al. (2007). Serotonin transporter binding after recovery from eating disorders. Psychopharmacology (Berlin) 195, 315-324.
13. Barbarich NC, McConaha CW, Halmi KA, Gendall K, et al. (2003). Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. International Journal of Eating Disorders 35, 10-15.
14. Barbee JG (2003). Topiramate in the treatment of bulimia nervosa with comorbid mood disorders: a case series. International Journal of Eating Disorders 33, 468-472. (Pubitemid 36397437)
15. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, et al. (2003). Predictors of weight loss in adults with topiramatetreated epilepsy. Obesity Research 11, 556-562. (Pubitemid 41202417)
16. Bernardi S, Pallanti S (2010). Successful duloxetine treatment of a binge eating disorder: a case report. Journal of Psychopharmacology 24, 1269-1272.
17. Biederman J, Herzog DB, Rivinus TM, Harper GP, et al. (1985). Amitriptyline in the treatment of anorexia nervosa. Journal of Clinical Psychopharmacology 5, 10-16.
18. Birmingham CL, Treasure J (2010). Medical Management of Eating Disorders, 2nd edn. Cambridge: Cambridge University Press.
19. Bissada H, Tasca GA, Barber AM, Bradwejn J (2008). Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 165, 1227-1228.
20. Bosanac P, Norman T, Burrows G, Beumont P (2005). Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics? Australian and New Zealand Journal of Psychiatry 39, 146-153. (Pubitemid 40425719)
21. Brambilla F, Garcia CS, Fassino S, Daga GA, et al. (2007). Olanzapine therapy in anorexia nervosa: psychobiological effects. International Clinical Psychopharmacology 22, 197-204. (Pubitemid 46801942)
22. Brennan BP, Roberts JA, Fogarty KV, Reynolds KA, et al. (2008). Memantine in the treatment of binge eating disorder: an open-label, prospective trial. International Journal of Eating Disorders 41, 520-526.
23. Broft AI, Spanos A, Corwin RL, Mayer L, et al. (2007). Baclofen for binge eating: an open-label trial. International Journal of Eating Disorders 40, 687-691. (Pubitemid 350106957)
24. Brownley KA, Berkman ND, Sedway JA, Lohr KN, et al. (2007). Binge eating disorder treatment: a systematic review of randomized controlled trials. International Journal of Eating Disorders 40, 337-348. (Pubitemid 46651308)
25. Bulik CM, Berkman ND, Brownley KA, Sedway JA, et al. (2007). Anorexia nervosa treatment: a systematic review of randomized controlled trials. International Journal of Eating Disorders 40, 310-320. (Pubitemid 46651306)
26. Chwastiak LA, Rosenheck RA, McEvoy JP Stroup TS, et al. (2009) The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry 31, 1-7.
27. Claudino A, Hay P, Lima MS, Bacaltchuk J, et al. (2006). Antidepressants for anorexia nervosa. Cochrane Database of Systematic Reviews. Issue 1, Art. No. CD004365.
28. Claudino AM, Bacaltchuk J, Hay PJ (2010). Pharmacotherapy for eating disorders. In: Paxton S, Hay P (Eds), Treatment Approaches for Body Dissatisfaction and Eating Disorders: Evidence and Practice (pp. 184-216). East Hawthorn: IP Communications.
29. Claudino AM, de Oliveira IR, Appolinario JC, Cordás TA, et al. (2007). Randomized, double-blind, placebocontrolled trial of topiramate plus cognitive-behavior therapy in binge eating disorder. Journal of Clinical Psychiatry 68, 1324-1332. (Pubitemid 47524510)
30. Connan F, Stanley S (2003). Biology of appetite and weight regulation. In: Treasure J, Schmidt U, van Furth E (Eds), Handbook of Eating Disorders, 2nd edn (pp. 63-67). Chichester, UK: Wiley.
31. Corcos M, Flament M, Atger F, Jeammet P (1996). Pharmacological treatment of bulimia nervosa. L'Encephale 12, 133-142. (Pubitemid 126613217)
32. Court A, Mulder C, Kerr M, Yuen HP, et al. (2010). Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. Journal of Psychiatric Research 44, 1027-1034.
33. de Zwaan M, Roerig J (2003). Pharmacological treatment of eating disorders: a review. In: Maj M, Halmi KA, López-Ibor JJ, Sartorius N (Eds), Eating Disorders (pp. 223-285) Chichester, UK: Wiley.
34. Devlin MJ, Goldfein JA, Jiang H, Raizman PS, et al. (2005). Cognitive behavioral therapy and fluoxetine as adjunct to group behavioral therapy for binge eating disorder. Obesity Research 13, 1077-1088.
35. Drewnowski A, Krahn DD, Demitrack MA, et al. (1995). Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. American Journal of Clinical Nutrition 61, 1206-1212.
36. Duncan KC, del Dotto D (2007). The role of olanzapine in the treatment of anorexia nervosa. Annals of Pharmacotherapy 41, 111-115. (Pubitemid 46145965)
37. El-Giamal N, de Zwaan M, Bailer U, Lennkh C, et al. (2000) Reboxetine in the treatment of bulimia nervosa: a report of seven cases. International Clinical Psychopharmacology 15, 351-356.
38. El-Giamal N, de Zwaan M, Bailer U, Strnad A, et al. (2003). Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. European Neuropsychopharmacology 13, 73-79. (Pubitemid 36313280)
39. Fassino F, Daga GA, Boggio S, Garzaro L, et al. (2004). Use of reboxetine in bulimia nervosa: a pilot study. Journal of Psychopharmacology 18, 423-428. (Pubitemid 39382572)
40. Fichter MM, Kruger R, Rief W, Holland R, et al. (1996). Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating specific psychopathology. Journal of Clinical Psychopharmacology 16, 9-18. (Pubitemid 26059163)
41. Fichter MM, Leibl K, Rief W, Brunner E, et al. (1991). Fluoxetine vs. placebo: a double blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 24, 1-7.
42. Fluoxetine Bulimia Nervosa Collaborative Study Group (1992). Fluoxetine in the treatment of bulimia nervosa: a multi-center, placebo-controlled, double-blind trial. Archives of General Psychiatry 49, 139-147.
43. Fontenelle LF, Vltor Mendlowicz M, de Menezes G, Papelbaum M, et al. (2003). Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder. Psychiatry Research 119, 189-194. (Pubitemid 36829433)
44. Freeman C (1998). Drug treatment for bulimia nervosa. Neuropsychobiology 37, 72-79. (Pubitemid 28143019)
45. Frieling H, Römer KD, Scholz S, Mittelbach F, et al. (2010). Epigenetic dysregulation of dopaminergic genes in eating disorders. International Journal of Eating Disorders 43, 577-583.
46. Giaquinto K, Capasso A, Petrella C, Milano W (2006). Comparative study between three different SSRIs in the treatment of bulimia nervosa. Pharmacology Online 1, 11-14.
47. Godart N, Perdereau F, Rein Z, Berthoz S, et al. (2007). Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. Journal of Affective Disorders 97, 37-49. (Pubitemid 44940821)
48. Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, et al. (2005). Effect of orlistat in obese patients with binge eating disorder. Obesity Research 3, 1701-1708.
49. Goldstein DJ, Wilson MG, Ascroft RC, al-Banna M (1999). Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. International Journal of Eating Disorders 25, 19-27. (Pubitemid 29031305)
50. Goldstein DJ, Wilson MG, Thomson VL, Potvin JH, et al. (1995). Long-term fluoxetine treatment of bulimia nervosa. British Journal of Psychiatry 166, 660-666.
51. Grilo CM, Masheb RM, Salant SL (2005b). Cognitive behavioural therapy guided self-help and Orlistat for the treatment of binge eating disorder: a randomized, doubleblind, placebo-controlled trial. Biological Psychiatry 57, 1193-1201. (Pubitemid 40615782)
52. Grilo MC, Masheb R, Wilson T (2005a). Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biological Psychiatry 57, 301-309. (Pubitemid 40187375)
53. Gross HA, Ebert MH, Faden VB, Goldberg SC, et al. (1981). A double-blind controlled trial of lithium carbonate primary anorexia nervosa. Journal of Clinical Psychopharmacology 1, 376-381. (Pubitemid 12189861)
54. Guerdjikova AI, McElroy SL, Kotwal R, Welge JA, et al. (2008). High-dose escitalopram in the treatment of bingeeating disorder with obesity: a placebo-controlled monotherapy trial. Human Psychopharmacology 23, 1-11. (Pubitemid 351166063)
55. Halmi KA, Agras WS, Crow S, Mitchell J, et al. (2005). Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Archives of General Psychiatry 62, 776-781. (Pubitemid 41002760)
56. Halmi KA, Eckert E, LaDu TJ, Cohen J (1986). Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Archives of General Psychiatry 43, 177-181. (Pubitemid 16163536)
57. Hay P, Mond J, Buttner P, Darby A (2008). Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia. PLOS One 6 Nov; 3, e1541.
58. Hay PJ, Claudino AC (2010a). Bulimia nervosa. Clinical Evidence Review Update 7, 1009.
59. Hay PJ, Claudino AC (2010b). Evidence-based treatment for the eating disorders. In: Agras S (Eds), Oxford Handbook of Eating Disorders (pp. 452-479). New York: Oxford University Press.
60. Hermanussen M, Tresguerres JAF (2003). Does the thrifty phenotype result from chronic glutamate intoxication? A hypothesis. Journal of Perinatal Medicine 31, 489-495. (Pubitemid 38057005)
61. Hudson JI, Hiripi E, Harrison G, Pope Jr. HG, Kessler RC (2007). The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biological Psychiatry 61, 348-358. (Pubitemid 46108682)
62. Hudson JI, Lalonde JK, Coit CE, Tsuang MT, et al. (2010). Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. American Journal of Clinical Nutrition 91, 1568-1573.
63. Hudson JI, McElroy SL, Raymond NC, Crow S, et al. (1998). Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. American Journal of Psychiatry 155, 1756-1762. (Pubitemid 28547503)
64. Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, et al. (2003a). Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. Journal of Clinical Psychiatry 64, 1449-1454. (Pubitemid 41270103)
65. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, et al. (2003b). Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. Journal of Clinical Psychiatry 64, 1335-1341. (Pubitemid 37490239)
66. Horne RL, Ferguson JM, Pope Jr. HG, Hudson JI, et al. (1988). Treatment of bulimia with bupropion: a multicenter controlled trial. Journal of Clinical Psychiatry 49, 262-266.
67. Hunt S, Russell A, Smithson WH, Parsons L, et al. (2008). Topiramate in pregnancy. Neurology 71, 272-276.
68. Jacobs-Pilipski MJ, Wilfley DE, Crow S, Walsh BT, et al. (2007). Placebo response in binge eating disorder. International Journal of Eating Disorders 40, 204-211. (Pubitemid 46466600)
69. James WP, Caterson ID, Coutinho W, Finer N, et al. (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine 363, 905-917.
70. Javaras KN, Pope HG, Lalonde JK, Roberts JL, et al. (2008) Co-occurrence of binge eating disorder with psychiatric and medical disorders. Journal of Clinical Psychiatry 69, 266-273. (Pubitemid 351469270)
71. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD (1992). Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Archives of General Psychiatry 49, 132-138.
72. Kaye W, Bulik C, Thornton L, Barbarich N, et al. (2004). Comorbidity of anxiety disorders with anorexia and bulimia nervosa. American Journal of Psychiatry 161, 2215-2221. (Pubitemid 39587286)
73. Kaye W, Gendall K, Strober M (1998). Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Journal of Biological Psychiatry 44, 825-838. (Pubitemid 28520221)
74. Kaye WH (2008). Neurobiology of anorexia and bulimia nervosa purdue ingestive behavior research center symposium influences on eating and body weight over the lifespan. Children and Adolescents Physiology and Behavior 94, 121-135.
75. Kaye WH, Frank GK, Bailer UF, Henry SE, et al. (2005). Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiology and Behavior 85, 73-81. (Pubitemid 40744978)
76. Kaye WH, Frank GK, McConaha C (1999). Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 21, 503-506. (Pubitemid 29414794)
77. Kaye WH, Nagata T, Weltzin TE, Hsu LK, et al. (2001). Double-blind placebo-controlled administration of fluoxetine in restricting-and purging-type anorexia nervosa. Biological Psychiatry 49, 644-652. (Pubitemid 32289359)
78. Lacey JH, Crisp AH (1980). Hunger, food intake and weight: the impact of clomipramine on a feeding anorexia nervosa population. Postgraduate Medical/Medicine Journal 56 (Suppl. 1), 79-85. (Pubitemid 10119391)
79. Laederach-Hofmann K, Graf C, Horber F, Lippuner K, et al. (1999). Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. International Journal of Eating Disorders 26, 231-244. (Pubitemid 29411691)
80. Lee Y, Lin P-Y (2010). Association between serotonin transporter gene polymorphism and eating disorders: a meta-analytic study. International Journal of Eating Disorders 43, 498-504.
81. Leggero C, Masi G, Brunori E, Calderoni S, et al. (2010). Low-dose olanzapine monotherapy in girls with anorexia nervosa restricting subtype: focus on hyperactivity. Journal of Child and Adolescent Psychopharmacology 20, 127-133.
82. Leombruni P, Amianto F, Delsedime N, Gramaglia C, et al. (2006). Citalopram vs. fluoxetine for the treatment of patients with bulimia nervosa. Advances in Therapy 23, 481-484.
83. Li Z, Maglione M, Tu W, Mojica W, et al. (2005). Metaanalysis: pharmacologic treatment of obesity. Annals of Internal Medicine 142, 532-546.
84. Lock JD, Fitzpatrick KK (2009). Anorexia nervosa. British Medical Journal Clinical Evidence 3, 1011.
85. Malhotra S, King KH, Welge JA, Brusman-Lovins L, et al. (2002). Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. Journal of Clinical Psychiatry 63, 802-826.
86. Marrazzi MA, Bacon JP, Kinzie J (1995a). Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. International Journal of Clinical Psychopharmacology 10, 163-172.
87. Marrazzi MA, Markham KM, Kinzie J, et al. (1995b). Binge eating disorder: response to naloxone. International Journal of Obesity 19, 143-145.
88. McElroy SL, Arnold LM, Shapira NA, Keck PE, et al. (2003b). Topiramate in the treatment of binge-eating disorder associated with obesity: a randomized, placebo-controlled trial. American Journal of Psychiatry 160, 255-261. (Pubitemid 41110450)
89. McElroy SL, Casuto LS, Nelson EB, Lake KA, et al. (2000). Placebo-controlled trial of sertraline in the treatment of binge eating disorder. American Journal of Psychiatry. 157, 1004-1006. (Pubitemid 30412354)
90. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, et al. (2007a). Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. Journal of Clinical Psychiatry 68, 390-398. (Pubitemid 46506803)
91. McElroy SL, Hudson JI, Capece JA, Beyers K, et al. (2007b). Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biological Psychiatry 61, 1039-1048. (Pubitemid 46551975)
92. McElroy SL, Hudson JI, Malhotra S, Weldge JA, et al. (2003a). Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. Journal of Clinical Psychiatry 64, 807-813. (Pubitemid 36897217)
93. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, et al. (2006). Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. Journal of Clinical Psychiatry 67, 1897-1906 (Pubitemid 46055195)
94. Erratum in: Journal of Clinical Psychiatry (2007) 68, 172.
95. McElroy SL, Shapira NA, Arnold LM, Keck PE, et al. (2004). Topiramate in the long-term treatment of binge eating disorder associated with obesity. Journal of Clinical Psychiatry 65, 1463-1469.
96. McKnight RF, Park RJ (2010). Atypical antipsychotics and anorexia nervosa: a review European eating. Disorders Review 18, 10-21.
97. Milano W, Petrella C, Capasso A (2005a). Treatment of bulimia nervosa with citalopram: a randomized controlled trial. Biomedical Research 16, 85-87. (Pubitemid 41248143)
98. Milano W, Petrella C, Casella A, Capasso A, et al. (2005c). Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge-eating disorder: a placebo-controlled study. Advances in Therapy 22, 25-31. (Pubitemid 40646917)
99. Milano W, Petrella C, Sabatino C, Capasso A (2004). Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Advances in Therapy 21, 232-237. (Pubitemid 39524900)
100. Milano W, Siano C, Petrella C, Sabatino C, et al. (2005b). Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Advances in Therapy 23, 278-283. (Pubitemid 41376940)
101. Mitchell JE, Christenson G, Jennings J, Huber M, et al. (1989). A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. Journal of Clinical Psychopharmacology 9, 94-97. (Pubitemid 19098154)
102. Mondraty N, Birmingham CL, Touyz S, Sundakov V, et al. (2005). Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australasian Psychiatry. 13, 72-75. (Pubitemid 40514990)
103. NICE (2004). Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related disorders. Clinical Guideline Number 9. London: National Institute for Clinical Excellence.
104. Nickel C, Tritt K, Muehlbacher M, Pedrosa GF, et al. (2005). Topiramate treatment in bulimia nervosa patients: a randomized, double-blind placebo-controlled trial. International Journal of Eating Disorders 38, 295-300. (Pubitemid 41785844)
105. Noma S, Uwatoko T, Yamamoto H, Hayashi T (2008). Effects of milnacipran on binge eating-a pilot study. Neuropsychiatric Disease and Treatment 4, 295-300. (Pubitemid 351460968)
106. Pearlstein T, Spurrell E, Holstein LA, Gurney V, et al. (2003). A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Archives of Womens Mental Health 6, 147-451.
107. Powers PS, Bannon Y, Eubanks R, McCormick T (2007). Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. International Journal of Eating Disorders. 40, 21-26. (Pubitemid 44936523)
108. Powers PS, Santana C (2004). Available pharmacological treatments for anorexia nervosa. Expert Opinion in Pharmacotherapy 5, 2287-2292. (Pubitemid 39489981)
109. Reas DL, Grilo CM (2008). Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity 16, 2024-2028.
110. Ricca V, Castellini C, Sauro CL, Rotella CM, et al. (2009). Zonisamide combined with cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychiatry 6, 23-28.
111. Ricca V, Mannucci E, Mezzani B, Moretti S, et al. (2001). Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychotherapy and Psychosomatics 70, 298-306. (Pubitemid 34701802)
112. Romano SJ, Halmi KA, Sarkar NP, Koke SC, et al. (2002). A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. American Journal of Psychiatry 159, 96-102. (Pubitemid 41070733)
113. Royal Australian and New Zealand College of Psychiatrists Clinical Practice (RANZCP) Guidelines Team for Anorexia Nervosa (2004). Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Australian and New Zealand Journal of Psychiatry 38, 659-670.
114. Ruggiero GM, Laini V, Mauri MC, Ferrari VMS, et al. (2001). A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25, 1049-1059. (Pubitemid 32769997)
115. Safer DL, Darcy AM, Lock J (2011). Use of mirtazepine in an adult with refractory anorexia nervosa and comorbid depression: a case report. International Journal of Eating Disorders 44, 178-181.
116. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, et al. (2007). Bulimia nervosa treatment. A systematic review of randomised controlled trials. International Journal of Eating Disorders 40, 321-336. (Pubitemid 46651307)
117. Stefano SC, Bacaltchuk J, Blay SL, Appolinário JC (2008). Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eating Behaviours 9, 129-136. (Pubitemid 351325722)
118. Steinglass J, Sysko R, Schebendach J, Brof A, et al. (2007). The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial. Journal of Psychiatric Practice 13, 238-245. (Pubitemid 47222146)
119. Strober M, Freeman R, Lampert C, Diamond J, et al. (2000). Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. American Journal of Psychiatry 157, 393-401. (Pubitemid 30145925)
120. Sysko R, Sha N, Wang Y, Duan N, et al. (2010). Early response to antidepressant treatment in bulimia nervosa. Psychological Medicine, 40, 999-1005.
121. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 101, 416-432. (Pubitemid 30365564)
122. Treasure J, Claudino A, Zucker N (2010). Eating disorders. Lancet 375, 583-593.
123. Trunko ME, Schwartz TA, Duvvuri V, Kaye WH (2010). Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. International Journal of Eating Disorders 44, 269-275.
124. Vandereycken W (1984). Neuroleptics in the short-term treatmente of anorexia nervosa, a double-blind placebocontrolled study with sulpiride. British Journal of Psychiatry 144, 288-292. (Pubitemid 14159403)
125. Vandereycken W, Pierloot R (1982). Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatrica Scandinavica 66, 445-450.
126. Vocks S, Tuschen-Caffier B, Pietrowsky R, Rustenbach SJ, et al. (2010). Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. International Journal of Eating Disorders 43, 205-217.
127. Wade TD, Bulik CM, Neale M, Kendler KS (2000). Anorexia nervosa and major depression: shared genetic and environmental risk factors. American Journal of Psychiatry 157, 469-471. (Pubitemid 30145940)
128. Walsh BT, Agras WS, Devlin MJ, Fairburn CG, et al. (2000). Fluoxetine for bulimia nervosa following poor response to psychotherapy. American Journal of Psychiatry 157, 523-531.
129. Walsh T, Kaplan AS, Attia E, Olmsted M, et al. (2006). Fluoxetine after weight restoration in anorexia nervosa. Journal of the American Medical Association 295, 2605-2612.
130. Wilfley DE, Crow S, Hudson JI, Mitchell JE, et al. (2008). Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. American Journal of Psychiatry 165, 51-58. (Pubitemid 351704552)